SOCIETAL ECONOMIC BURDEN AND TREATMENT VALUE OF HEMOPHILIA A IN MOROCCO: AN EXPLORATORY PILOT STUDY USING HUMAN CAPITAL AND INPUT-OUTPUT ANALYSIS
Author(s)
Omar Maoujoud, PhD, MD1, sanaa haouraji, Msc2;
1Research team of Pharmacoeconomics & Pharmacoepidemiology, Moroccan Society of health economics (SMEPS), Faculty of Medicine, Mohamed V university, Rabat, Morocco, 2EOS Executive Lab, Casablanca, Morocco
1Research team of Pharmacoeconomics & Pharmacoepidemiology, Moroccan Society of health economics (SMEPS), Faculty of Medicine, Mohamed V university, Rabat, Morocco, 2EOS Executive Lab, Casablanca, Morocco
OBJECTIVES: Hemophilia A imposes substantial productivity losses, yet the societal economic burden remains unquantified in Morocco. This exploratory pilot study aimed to estimate annual productivity loss attributable to hemophilia A and provide preliminary estimates of the societal value of expanding prophylaxis coverage.
METHODS: A pilot social impact model was developed integrating the Human Capital Approach (Becker, 1964) with Leontief Input-Output framework, following ISPOR Task Force recommendations. Epidemiological inputs from expert consultation: estimated population 4,400 patients (45% severe; 58% working-age); current prophylaxis coverage 20% (880 patients); treatment gap 80%. Productivity parameters from Morocco High Commission for Planning: gross value added, labor force participation, formal/informal sector distribution. Economic multipliers calibrated to Moroccan inter-industry structure: direct 1.0x, indirect 0.58x, induced 0.42x (cumulative 2.0x). Productivity loss was decomposed into four pillars: direct paid work, indirect supply-chain, induced consumption, and unpaid domestic work. Scenario analysis compared current coverage (20%) versus expansion (80%). Twenty-year ROI was estimated with breakeven analysis.
RESULTS: Total annual societal burden: $34.8 million, comprising direct paid work loss ($13.8M, 39.7%), indirect supply-chain effects ($8.0M, 23.0%), induced consumption loss ($5.8M, 16.7%), and unpaid work loss ($7.2M, 20.7%). Current prophylaxis generates $475,000 annual societal value. Expanding coverage to 80% (3,520 patients) would generate $1.90 million annually (+$1.43M/year, 4-fold increase). Required investment for 2,640 additional patients: $158.4 million annually. Total annual benefits: $75.2 million. Estimated breakeven: 15-17 years. Projected twenty-year ROI: +10.5%.
CONCLUSIONS: This exploratory analysis suggests hemophilia A imposes $34.8 million annual productivity burden in Morocco with 80% treatment gap. Preliminary findings indicate prophylaxis expansion may generate positive long-term ROI. Results require validation with national registry data. Priority: establish national hemophilia registry and conduct local studies to refine parameters.
METHODS: A pilot social impact model was developed integrating the Human Capital Approach (Becker, 1964) with Leontief Input-Output framework, following ISPOR Task Force recommendations. Epidemiological inputs from expert consultation: estimated population 4,400 patients (45% severe; 58% working-age); current prophylaxis coverage 20% (880 patients); treatment gap 80%. Productivity parameters from Morocco High Commission for Planning: gross value added, labor force participation, formal/informal sector distribution. Economic multipliers calibrated to Moroccan inter-industry structure: direct 1.0x, indirect 0.58x, induced 0.42x (cumulative 2.0x). Productivity loss was decomposed into four pillars: direct paid work, indirect supply-chain, induced consumption, and unpaid domestic work. Scenario analysis compared current coverage (20%) versus expansion (80%). Twenty-year ROI was estimated with breakeven analysis.
RESULTS: Total annual societal burden: $34.8 million, comprising direct paid work loss ($13.8M, 39.7%), indirect supply-chain effects ($8.0M, 23.0%), induced consumption loss ($5.8M, 16.7%), and unpaid work loss ($7.2M, 20.7%). Current prophylaxis generates $475,000 annual societal value. Expanding coverage to 80% (3,520 patients) would generate $1.90 million annually (+$1.43M/year, 4-fold increase). Required investment for 2,640 additional patients: $158.4 million annually. Total annual benefits: $75.2 million. Estimated breakeven: 15-17 years. Projected twenty-year ROI: +10.5%.
CONCLUSIONS: This exploratory analysis suggests hemophilia A imposes $34.8 million annual productivity burden in Morocco with 80% treatment gap. Preliminary findings indicate prophylaxis expansion may generate positive long-term ROI. Results require validation with national registry data. Priority: establish national hemophilia registry and conduct local studies to refine parameters.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE279
Topic
Economic Evaluation
Topic Subcategory
Novel & Social Elements of Value, Value of Information, Work & Home Productivity - Indirect Costs
Disease
SDC: Rare & Orphan Diseases, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)